Ability Biotherapeutics (also known as Ability Biologics) is a Montreal-based biotech founded in 2023 that engineers highly selective, immune-cell-modulating antibody therapeutics for cancer and autoimmune disease. Its AbiLeap discovery engine pairs continuously learning AI with one of the largest antibody-antigen interaction databases ever assembled to generate fully human, IgG-based multispecific antibodies that sense their environment and act only where intended - so-called logic-gated therapeutics. Backed by US$18M in seed capital led by Amplitude Ventures, the company is advancing a pipeline of immuno-oncology and autoimmune candidates toward preclinical readiness.
Fortitude Biomedicines is a Waltham, Massachusetts biotech that launched in early 2026 with $13M in seed financing to develop next-generation antibody-based therapies for autoimmune diseases and cancer. Its proprietary GLUE-DAC platform bolts molecular glue degraders onto antibody-drug conjugates, aiming to use catalytic targeted protein degradation to widen the therapeutic window of ADCs and overcome the resistance that has dogged the field. Its lead program, FORT-202, is a first-in-class T-cell targeting bispecific antibody for axial spondyloarthritis expected to reach the clinic in the first half of 2027.
GEMMA Biotherapeutics (GEMMABio) is a Philadelphia-based gene therapy company spun out of the University of Pennsylvania and founded by AAV pioneer James M. Wilson. Launched in October 2024 with $34 million in seed funding, GEMMABio builds the research, manufacturing, and product-development infrastructure to move adeno-associated virus (AAV) gene therapies from the bench to the bedside faster and more affordably - with a focus on rare and ultra-orphan inherited diseases and a stated commitment to global patient access.
Geneos Therapeutics is a clinical-stage biotherapeutics company in Plymouth Meeting / Philadelphia, Pennsylvania, building DNA-based personalized immunotherapies for cancer. Its proprietary GT-EPIC platform reads a patient's own tumor mutations and manufactures a custom DNA plasmid vaccine encoding up to 40 of that patient's unique neoantigens, delivered intradermally with an IL-12 cytokine adjuvant and electroporation. In 2024 the company published Phase 1/2 GT-30 data in Nature Medicine showing its vaccine plus pembrolizumab generated new neoantigen-specific T cells and clinical responses in advanced liver cancer - billed as the first definitive demonstration of a personalized cancer vaccine boosting response to anti-PD-1 therapy.